Abstract
Greater understanding of the genetic determinants of drug response can change the use of many drug treatments by influencing the pharmacokinetics of drugs that can impact an individual's response to medicinal therapies. Additionally, proper medicine selection and dose can help to improve patient care. Individualized cancer therapy can be achieved for most cancer patients by identifying people at risk for severe toxicity and those that are likely to benefit from a particular treatment. However, extensive research is required to acquire a complete grasp of polymorphism and pharmacogenetics markers. There are genetically inherited variants in pharmacokinetic profile (absorption, distribution, metabolism, and excretion) of enzymes or proteins including dihydropyrimidine dehydrogenase (DPD), thiopurine S-methyltransferase (TPMT), UDP-glucuronosyltransferase (UGT1A1), in modeling inherited adverse outcomes, as well as therapeutic signaling molecule (ABCB1, ABCG2, and ABCC of ATP-binding cassette transporters) and target enzymes in predicting drug efficacy with respect to both cytotoxic agents and targeted agents. This chapter mainly focused on how the drug transporter and drug-metabolizing enzymes genetic variance and other contributing factors influences the pharmacokinetic profile of the anticancer medicines.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
